Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Tabula Rasa HealthCare Creates Office of Strategy Development and Names New General Counsel

Posted on: 11 Oct 16

MOORESTOWN, N.J., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare (NASDAQ:TRHC) Chairman and CEO Calvin H. Knowlton, PhD, today announced changes to TRHC’s corporate C-suite.

Current General Counsel and Chief Strategy Officer, Brian J. Litten, Esq., is being promoted to lead the new Office of Strategy Development (OSD). In this expanded role, Litten will retain his title of Chief Strategy Officer. He will oversee all product development, sales and implementation focused on new markets outside of the company’s PACE (Programs of All-Inclusive Care for the Elderly) market.  The OSD team will be developed over the next six months.

The OSD was created to formalize the expansion of TRHC’s Medication Risk Mitigation™ platform. According to CEO Knowlton, the OSD will target markets for TRHC’s Medication Risk Mitigation (MRM) platform, which are separate from its ongoing PACE market. “We have asked Brian Litten, Esq., formerly a health insurance company executive, to lead this new initiative under his continued title as Chief Strategy Officer,” Knowlton reported.

“We also are pleased to announce Kevin J. Dill, Esq., will serve as TRHC’s General Counsel and Chief Compliance Officer,” Knowlton said. “Kevin brings valuable public-company experience in the areas of risk assessment, compliance oversight, and efficiency of healthcare operations.  I have asked Brian and Kevin to collaborate over the next few months to transition TRHC’s legal work to the Office of General Counsel.   Until the completion of this transition, Brian will continue to serve as our General Counsel, while building the new Office of Strategic Development.”

Dill comes to TRHC from Olympus Corporations of the Americas, where he served as Chief Compliance Officer handling implementation of comprehensive compliance procedures and assessments across Americas for the $2.5B medical device and consumer products company with a field force of over 1,000 sales representatives and distributor network. He is recognized for leading healthcare businesses in design and execution of strategies that ensure operations are in full compliance with laws and regulations, and for providing guidance to company executives and Board of Directors on compliance risks and remediation strategies.

Dill received a Juris Doctor (JD) degree from Temple University, Beasley School of Law, Philadelphia, PA; Doctor of Ministry (DMin), Princeton Theological Seminary; and Bachelor of Arts (BA), Gettysburg College, Gettysburg, PA.

Dill will begin his tenure at TRHC starting October 17, 2016. 

About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit:


Last updated on: 12/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.